To further evaluate whether CDK9 inhibition is sufficient to re-sensitize colon cancer cells to TRAIL-induced cell death, three TRAIL-resistant CRC cell lines were preincubated with Dinaciclib prior to TRAIL treatment. The gene discussed is CDK9; the disease is malignant colon neoplasm.